• 제목/요약/키워드: Patient specific QA

검색결과 31건 처리시간 0.025초

Clinical performance of FractionLab in patient-specific quality assurance for intensity-modulated radiotherapy : a retrospective study

  • Oh, Se An;Kim, Sung Yeop;Park, Jaehyeon;Park, Jae Won;Yea, Ji Woon
    • Journal of Yeungnam Medical Science
    • /
    • 제39권2호
    • /
    • pp.108-115
    • /
    • 2022
  • Background: This study was aimed at comparing and analyzing the results of FractionLab (Varian/Mobius Medical System) with those of portal dosimetry that uses an electronic portal imaging device. Portal dosimetry is extensively used for patient-specific quality assurance (QA) in intensity-modulated radiotherapy (IMRT). Methods: The study includes 29 patients who underwent IMRT on a Novalis-Tx linear accelerator (Varian Medical System and Brain-LAB) between June 2019 and March 2021. We analyzed the multileaf collimator DynaLog files generated after portal dosimetry to evaluate the same condition using FractionLab. The results of the recently launched FractionLab at various gamma indices (0.1%/0.1 mm-1%/1 mm) are analyzed and compared with those of portal dosimetry (3%/3 mm). Results: The average gamma passing rates of portal dosimetry (3%/3 mm) and FractionLab are 98.1% (95.5%-100%) and 97.5% (92.3%-99.7%) at 0.6%/0.6 mm, respectively. The results of portal dosimetry (3%/3 mm) are statistically comparable with the QA results of FractionLab (0.6%/0.6 mm-0.9%/0.9 mm). Conclusion: This paper presents the clinical performance of FractionLab by the comparison of the QA results of FractionLab using portal dosimetry with various gamma indexes when performing patient-specific QA in IMRT treatment. Further, the appropriate gamma index when performing patient-specific QA with FractionLab is provided.

Clinical implementation of PerFRACTIONTM for pre-treatment patient-specific quality assurance

  • Sang-Won Kang;Boram Lee;Changhoon Song;Keun-Yong Eeom;Bum-Sup Jang;In Ah Kim;Jae-Sung Kim;Jin-Beom Chung;Seonghee Kang;Woong Cho;Dong-Suk Shin;Jin-Young Kim;Minsoo Chun
    • Journal of the Korean Physical Society
    • /
    • 제80권
    • /
    • pp.516-525
    • /
    • 2022
  • This study is to assess the clinical use of commercial PerFRACTIONTM for patient-specific quality assurance of volumetric-modulated arc therapy. Forty-six pretreatment verification plans for patients treated using a TrueBeam STx linear accelerator for lesions in various treatment sites such as brain, head and neck (H&N), prostate, and lung were included in this study. All pretreatment verification plans were generated using the Eclipse treatment planning system (TPS). Dose distributions obtained from electronic portal imaging device (EPID), ArcCHECKTM, and two-dimensional (2D)/three-dimensional (3D) PerFRACTIONTM were then compared with the dose distribution calculated from the Eclipse TPS. In addition, the correlation between the plan complexity (the modulation complexity score and the leaf travel modulation complexity score) and the gamma passing rates (GPRs) of each quality assurance (QA) system was evaluated by calculating Spearman's rank correlation coefficient (rs) with the corresponding p-values. The gamma passing rates of 46 patients analyzed with the 2D/3D PerFRACTIONTM using the 2%/2 mm and 3%/3 mm criteria showed almost similar trends to those analyzed with the Portal dose imaging prediction (PDIP) and ArcCHECKTM except for those analyzed with ArcCHECKTM using the 2%/2 mm criterion. Most of weak or moderate correlations between GPRs and plan complexity were observed for all QA systems. The trend of mean rs between GPRs using PDIP and 2D/3D PerFRACTIONTM for both criteria and plan complexity indices as in the GPRs analysis was significantly similar for brain, prostate, and lung cases with lower complexity compared to H&N case. Furthermore, the trend of mean rs for 2D/3D PerFRACTIONTM for H&N case with high complexity was similar to that of ArcCHECKTM and slightly lower correlation was observed than that of PDIP. This work showed that the performance of 2D/3D PerFRACTIONTM for pretreatment patient-specific QA was almost comparable to that of PDIP, although there was small difference from ArcCHECKTM for some cases. Thus, we found that the PerFRACTIONTM is a suitable QA system for pretreatment patient-specific QA in a variety of treatment sites.

Clinical Implementation of 3D Printing in the Construction of Patient Specific Bolus for Photon Beam Radiotherapy for Mycosis Fungoides

  • Kim, Sung-woo;Kwak, Jungwon;Cho, Byungchul;Song, Si Yeol;Lee, Sang-wook;Jeong, Chiyoung
    • 한국의학물리학회지:의학물리
    • /
    • 제28권1호
    • /
    • pp.33-38
    • /
    • 2017
  • Creating individualized build-up material for superficial photon beam radiation therapy at irregular surface is complex with rice or commonly used flat shape bolus. In this study, we implemented a workflow using 3D printed patient specific bolus and describe our clinical experience. To provide better fitted build-up to irregular surface, the 3D printing technique was used. The PolyLactic Acid (PLA) which processed with nontoxic plant component was used for 3D printer filament material for clinical usage. The 3D printed bolus was designed using virtual bolus structure delineated on patient CT images. Dose distributions were generated from treatment plan for bolus assigned uniform relative electron density and bolus using relative electron density from CT image and compared to evaluate the inhomogeneity effect of bolus material. Pretreatment QA is performed to verify the relative electron density applied to bolus structure by gamma analysis. As an in-vivo dosimetry, Optically Stimulated Luminescent Dosimeters (OSLD) are used to measure the skin dose. The plan comparison result shows that discrepancies between the virtual bolus plan and printed bolus plan are negligible. (0.3% maximum dose difference and 0.2% mean dose difference). The dose distribution is evaluated with gamma method (2%, 2 mm) at the center of GTV and the passing rate was 99.6%. The OSLD measurement shows 0.3% to 2.1% higher than expected dose at patient treatment lesion. In this study, we treated Mycosis fungoides patient with patient specific bolus using 3D printing technique. The accuracy of treatment plan was verified by pretreatment QA and in-vivo dosimetry. The QA results and 4 month follow up result shows the radiation treatment using 3D printing bolus is feasible to treat irregular patient skin.

방사선치료계획 정도관리 방법에 따른 신뢰도 평가 (Reliability estimation about quality assurance method of radiotherapy planning)

  • 김정호;김가중;유세종;김기진
    • 대한안전경영과학회지
    • /
    • 제17권1호
    • /
    • pp.119-124
    • /
    • 2015
  • According as radiation therapy technique develops, standardization of radiation therapy has been complicated by the plan QA(Quality Assurance). However, plan QA tools are two type, OADT (opposite accumulation dose tool) and 3DADT (3 dimensional accumulation dose tool). OADT is not applied to evaluation of beam path. Therefore tolerance error of beam path will establish measurement value at OADT. Plan is six beam path, five irradiation field at each beam path. And beam path error is 0 degree, 0.2 degree, 0.4 degree, 0.6 degree, 0.6 degree, 0.8 degree. Plan QA accomplishes at OADT, 3DADT. The more path error increases, the more plan QA error increases. Tolerance error of OADT path is 0.357 using tolerance error of conventional plan QA. Henceforth plan QA using OADT will include beam path error. In addition, It will increase reliability through precise and various plan technique.

Optimal Density Assignment to 2D Diode Array Detector for Different Dose Calculation Algorithms in Patient Specific VMAT QA

  • Park, So-Yeon;Park, Jong Min;Choi, Chang Heon;Chun, Minsoo;Han, Ji Hye;Cho, Jin Dong;Kim, Jung-in
    • Journal of Radiation Protection and Research
    • /
    • 제42권1호
    • /
    • pp.9-15
    • /
    • 2017
  • Background: The purpose of this study is to assign an appropriate density to virtual phantom for 2D diode array detector with different dose calculation algorithms to guarantee the accuracy of patient-specific QA. Materials and Methods: Ten VMAT plans with 6 MV photon beam and ten VMAT plans with 15 MV photon beam were selected retrospectively. The computed tomography (CT) images of MapCHECK2 with MapPHAN were acquired to design the virtual phantom images. For all plans, dose distributions were calculated for the virtual phantoms with four different materials by AAA and AXB algorithms. The four materials were polystyrene, 455 HU, Jursinic phantom, and PVC. Passing rates for several gamma criteria were calculated by comparing the measured dose distribution with calculated dose distributions of four materials. Results and Discussion: For validation of AXB modeling in clinic, the mean percentages of agreement in the cases of dose difference criteria of 1.0% and 2.0% for 6 MV were $97.2%{\pm}2.3%$, and $99.4%{\pm}1.1%$, respectively while those for 15 MV were $98.5%{\pm}0.85%$ and $99.8%{\pm}0.2%$, respectively. In the case of 2%/2 mm, all mean passing rates were more than 96.0% and 97.2% for 6 MV and 15 MV, respectively, regardless of the virtual phantoms of different materials and dose calculation algorithms. The passing rates in all criteria slightly increased for AXB as well as AAA when using 455 HU rather than polystyrene. Conclusion: The virtual phantom which had a 455 HU values showed high passing rates for all gamma criteria. To guarantee the accuracy of patent-specific VMAT QA, each institution should fine-tune the mass density or HU values of this device.

세기변조방사선치료의 품질관리를 위한 이온전리함 매트릭스의 유용성 고찰 (Feasibility of MatriXX for Intensity Modulated Radiation Therapy Quality Assurance)

  • 강민영;김연래;박병문;배용기;방동완
    • 대한방사선치료학회지
    • /
    • 제19권2호
    • /
    • pp.91-97
    • /
    • 2007
  • 목 적: 세기변조방사선치료 시 선행되는 품질관리에서 선량분포와 절대선량 값을 비교하여 2차원 이온전리함의 유용성을 알아보고자 한다. 대상 및 방법: 본 실험은 선형가속기(CL 21EX, Varian, Palo Alto, USA)의 6 MV 광자선을 이용하여 비인두암 환자를 대상으로 하였다. 세기변조방사선치료를 위한 품질관리에는 2차원 이온전리함 배열(MatriXX, Wellhofer Dosimetrie, Germany)을 사용하였다. 비인두암 환자의 치료를 위해 역방향치료계획을 시행하였다. 고체팬톰에 삽입된 MatriXX를 전산화단층 촬영하여 환자 치료계획과 동일한 플루언스로 하이브리드(갠트리 각도 0$^\circ$) 치료계획을 실시하였다. 실험적 선량분포의 측정은 하이브리드 치료계획과 동일한 기하학적 조건으로 MatriXX와 고체팬톰을 이용하여 측정하였다. 선량분포에서 고선량 저변위(High Dose Low Gradient: HDLG) 점을 선정하여 절대선량을 비교하였으며, 선량분포 일치성분석을 위해 감마 인덱스 히스토그람($\gamma$-index, Dose difference: 3%, Distance to agreement: 3 mm)을 이용하여 정량화하였다. 결 과: 감마 인덱스 히스토그람 분석결과 인정허용범위(${\gamma}{\leq}$1) 비율을 모든 조사면에서 각각 확인하였다. 갠트리 각도 0$^\circ$에서 95.08%, 55$^\circ$에서 97.52%, 110$^\circ$에서 96.28%, 140$^\circ$에서 98.2%, 220$^\circ$에서 97.78%, 250$^\circ$에서 96.64%, 305$^\circ$에서 92.7%로 나타났다. HDLG에서 절대선량은 $\pm$3% 이내의 일치도를 보였다. 결 론: MatriXX를 이용한 세기변조방사선치료의 품질관리는 필름이나 단일 이온전리함을 이용한 일반적인 세기변조방사선치료 품질관리에 비해 시간, 인력을 최소화하면서 보다 효율적인 접근이 가능하였으며, 선량분포일치성 분석 및 절대선량확인에 매우 유용한 장치임을 알 수 있었다.

  • PDF

호흡동조 방사선치료의 2차원 선량 분포 정도관리를 위한 4D 정도관리 시스템 개발 (The Clinical Implementation of 2D Dose Distribution QA System for the Patient Specific Respiratory-gated Radiotherapy)

  • 김진성;신은혁;신정석;주상규;한영이;박희철;최두호
    • 한국의학물리학회지:의학물리
    • /
    • 제21권2호
    • /
    • pp.127-136
    • /
    • 2010
  • 최근 시행되고 있는 호흡동조 방사선치료는 환자의 호흡의 주기를 이용하여 일정 주기에만 방사선을 조사하는 최신 방사선치료기술로 4D Computed Tomography와 RPM (Real-time Position Management) 시스템과 같은 호흡 모니터링 시스템의 개발로 환자들에게 시행이 되고 있다. 그러나 이러한 호흡동조 방사선치료에 대한 정도 관리는 아직 체계적으로 수행되고 있지 않으며 특히 환자에게 계획된 방사선치료선량이 환자의 호흡에 따라서 치료계획된 대로 조사되는지에 대한 정도관리에 대한 필요성이 요구되고 있다. 따라서 본 기관에서는 환자의 호흡신호를 사용하여 환자의 움직임을 동일하게 모사할 수 있는 팬텀을 제작하여 호흡동조 방사선치료의 2차원적 선량 분포를 평가할 수 있는 시스템을 구축하였고 특정환자의 호흡신호와 방사선치료계획을 이용하여 검증하였다. 환자의 호흡신호는 LabVIEW 7.0을 이용하여 모사하였고, 자체 제작한 팬텀 및 Kodak EDR2 필름을 사용하여 방사선을 조사한 뒤 gamma index를 사용하여 2차원 선량 분포를 비교 분석하였다. 본 연구에서 개발된 4D 정도관리 시스템을 좀 더 보완하여 호흡동조 방사선치료 과정에 있어서 조사선량의 적정성을 평가할 수 있는 정도관리 시스템으로 사용할 수 있을 것이라 생각된다.

Initial Experience of Patient-Specific QA for Wobbling and Line-Scanning Proton Therapy at Samsung Medical Center

  • Jo, Kwanghyun;Ahn, Sung Hwan;Chung, Kwangzoo;Cho, Sungkoo;Shin, Eun Hyuk;Park, Seyjoon;Hong, Chae-Seon;Kim, Dae-Hyun;Lee, Boram;Lee, Woojin;Choi, Doo Ho;Lim, Do Hoon;Pyo, Hong Ryull;Han, Youngyih
    • 한국의학물리학회지:의학물리
    • /
    • 제30권1호
    • /
    • pp.14-21
    • /
    • 2019
  • Purpose: To report the initial experience of patient-specific quality assurance (pQA) for the wobbling and line-scanning proton therapy at Samsung Medical Center. Materials and Methods: The pQA results of 89 wobbling treatments with 227 fields and 44 line-scanning treatments with 118 fields were analyzed from December 2015 to June 2016. For the wobbling method, proton range and spread-out Bragg peak (SOBP) width were verified. For the line-scanning method, output and two-dimensional dose distribution at multiple depths were verified by gamma analysis with 3%/3 mm criterion. Results: The average range difference was -0.44 mm with a standard deviation (SD) of 1.64 mm and 0.1 mm with an SD of 0.53 mm for the small and middle wobbling radii, respectively. For the line-scanning method, the output difference was within ${\pm}3%$. The gamma passing rates were over 95% with 3%/3 mm criterion for all depths. Conclusions: For the wobbling method, proton range and SOBP width were within the tolerance levels. For the line-scanning method, the output and two-dimensional dose distribution showed excellent agreement with the treatment plans.

사이버나이프의 품질관리 절차서 개발 (The Development of Quality Assurance Program for CyberKnife)

  • 장지선;강영남;신동오;김문찬;윤세철;최일봉;김미숙;조철구;류성렬;권수일;이동한
    • Radiation Oncology Journal
    • /
    • 제24권3호
    • /
    • pp.185-191
    • /
    • 2006
  • 목 적: 국내 실정에 적합한 사이버나이프의 표준화된 품질관리 절차서가 없어 이를 개발하고 유용성을 평가하고자 한다. 대상 및 방법: 사이버나이프의 구조적 특성과 치료 방법 등을 고려하여 품질관리 검사항목을 설정한 후, 적합한 시행 시기에 맞추어 주기적 분류를 하였다. 그리고 설정된 항목들은 각각의 품질관리 목적에 따라 일반적인 품질관리(basic QC), 치료정확도 품질관리(delivery specific QC), 환자 맞춤형 품질관리(patient specific QC) 등 3개의 분야로 구분하였다. 국내의 두 개 기관을 대상으로 개발된 품질관리 절차서의 각 항목을 비교하여 허용오차를 분석하였다. 설정된 항목에 대한 허용 오차는 제작사에서 제공된 품질관리 자료와 현재 국내에 설치되어 있는 두 개 기관의 최근 3년간의 품질관리 수행 데이터 등을 근거하였으며, 각 항목에 대한 측정 결과를 토대로 품질관리 실태를 분석하고 개발된 품질관리 절차서의 타당성을 검증하였다. 결 과: 개발된 사이버나이프 품질관리 절차서의 항목에 대하여 두 개 기관을 대상으로 정확성을 상호 비교 분석하였다. 모든 측정 결과는 사이버나이프의 품질관리 절차서에서 제시한 허용오차 범위 내에서 일치하고 있음을 확인하였다. 결 론: 본 연구에서 개발된 품질관리 절차서를 통해 사이버나이프에 대한 성능평가 기준을 확립할 수 있으며, 영상유도 정위방사선치료에 대한 정확성 및 안전성을 확보할 수 있을 것으로 생각된다.

Uncertainty Assessment: Relative versus Absolute Point Dose Measurement for Patient Specific Quality Assurance in EBRT

  • Mahmood, Talat;Ibrahim, Mounir;Aqeel, Muhammad
    • 한국의학물리학회지:의학물리
    • /
    • 제28권3호
    • /
    • pp.111-121
    • /
    • 2017
  • Verification of dose distribution is an essential part of ensuring the treatment planning system's (TPS) calculated dose will achieve the desired outcome in radiation therapy. Each measurement have uncertainty associated with it. It is desirable to reduce the measurement uncertainty. A best approach is to reduce the uncertainty associated with each step of the process to keep the total uncertainty under acceptable limits. Point dose patient specific quality assurance (QA) is recommended by American Association of Medical Physicists (AAPM) and European Society for Radiotherapy and Oncology (ESTRO) for all the complex radiation therapy treatment techniques. Relative and absolute point dose measurement methods are used to verify the TPS computed dose. Relative and absolute point dose measurement techniques have a number of steps to measure the point dose which includes chamber cross calibration, electrometer reading, chamber calibration coefficient, beam quality correction factor, reference conditions, influences quantities, machine stability, nominal calibration factor (for relative method) and absolute dose calibration of machine. Keeping these parameters in mind, the estimated relative percentage uncertainty associated with the absolute point dose measurement is 2.1% (k=1). On the other hand, the relative percentage uncertainty associated with the relative point dose verification method is estimated to 1.0% (k=1). To compare both point dose measurement methods, 13 head and neck (H&N) IMRT patients were selected. A point dose for each patient was measured with both methods. The average percentage difference between TPS computed dose and measured absolute relative point dose was 1.4% and 1% respectively. The results of this comparative study show that while choosing the relative or absolute point dose measurement technique, both techniques can produce similar results for H&N IMRT treatment plans. There is no statistically significant difference between both point dose verification methods based upon the t-test for comparing two means.